Genequantum collaborates with Aimedbio to develop ADC for brain tumors April 20, 2022 By Doris Yu and Gina Lee Genequantum Healthcare Co. Ltd. will work with Aimedbio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023. Read More
MJFF grant supports Neuropore's development of TLR2 antagonist for Parkinson's disease April 20, 2022
Ono establishes collaborations to discover small molecules targeting GPCRs in metabolic disease April 20, 2022
Engitix expands collaboration with Takeda to include therapeutics for fibrostenotic IBD April 13, 2022
AAHI receives donation to support development of next-generation vaccine and therapeutic solutions April 12, 2022
Artiva and Merck & Co. agree to evaluate combinations of NK cells with trispecific NK-cell engagers April 12, 2022
RSS